SG11201603063WA - Compounds for use in prevention and treatment of neurodegenerative diseases and pain - Google Patents
Compounds for use in prevention and treatment of neurodegenerative diseases and painInfo
- Publication number
- SG11201603063WA SG11201603063WA SG11201603063WA SG11201603063WA SG11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA
- Authority
- SG
- Singapore
- Prior art keywords
- pain
- prevention
- compounds
- treatment
- neurodegenerative diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361894699P | 2013-10-23 | 2013-10-23 | |
PCT/US2014/061734 WO2015061426A1 (fr) | 2013-10-23 | 2014-10-22 | Composés destinés à être utilisés dans la prévention et le traitement de maladies neurodégénératives et de la douleur |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201603063WA true SG11201603063WA (en) | 2016-05-30 |
Family
ID=52993493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603063WA SG11201603063WA (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
Country Status (14)
Country | Link |
---|---|
US (1) | US10301348B2 (fr) |
EP (1) | EP3060566B1 (fr) |
JP (1) | JP6534997B2 (fr) |
KR (1) | KR102313314B1 (fr) |
CN (1) | CN106414456B (fr) |
AU (1) | AU2014340114B2 (fr) |
BR (1) | BR112016008901B1 (fr) |
CA (1) | CA2927699C (fr) |
IL (1) | IL245103B (fr) |
MX (1) | MX367707B (fr) |
RU (1) | RU2695358C2 (fr) |
SG (1) | SG11201603063WA (fr) |
WO (1) | WO2015061426A1 (fr) |
ZA (1) | ZA201603118B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016196012A1 (fr) | 2015-05-29 | 2016-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Agents nucléosidiques pour la réduction de l'activité délétère de gènes contenant une répétition de nucléotide étendue |
WO2018140734A1 (fr) | 2017-01-27 | 2018-08-02 | Academia Sinica | Composé à effet analgésique destiné à être utilisé dans la prévention et le traitement de la douleur |
TW202400186A (zh) * | 2022-02-10 | 2024-01-01 | 中央研究院 | 治療脊髓損傷之方法及用於其中之組成物 |
WO2024010910A1 (fr) * | 2022-07-07 | 2024-01-11 | Academia Sinica | Méthode de traitement de la schizophrénie et composition à cet effet |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988003148A2 (fr) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Derives heteroaromatiques d'adenosine |
US5034381A (en) * | 1988-01-07 | 1991-07-23 | Ciba-Geigy Corporation | 2-(substituted amino) adenosines as antihypertensives |
US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
WO1992005177A1 (fr) * | 1990-09-25 | 1992-04-02 | Rhone-Poulenc Rorer International (Holdings) Inc. | Composes possedant des proprietes anti-hypertensives et anti-ischemiques |
UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
HUE035188T2 (en) * | 2009-11-13 | 2018-05-02 | Academia Sinica | Adenosine A2A receptor and adenzoin transporter double acting compounds for the prevention and treatment of neurodegenerative diseases |
US10174033B2 (en) * | 2009-12-10 | 2019-01-08 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof |
AU2013216773B2 (en) | 2012-02-09 | 2016-06-09 | Brandbumps, Llc | Decorative detectable warning panel having improved grip |
US20150038445A1 (en) * | 2012-02-11 | 2015-02-05 | Academia Sinica | Methods and compositions for treating pain |
-
2014
- 2014-10-22 SG SG11201603063WA patent/SG11201603063WA/en unknown
- 2014-10-22 CA CA2927699A patent/CA2927699C/fr active Active
- 2014-10-22 JP JP2016525563A patent/JP6534997B2/ja active Active
- 2014-10-22 AU AU2014340114A patent/AU2014340114B2/en active Active
- 2014-10-22 BR BR112016008901-4A patent/BR112016008901B1/pt active IP Right Grant
- 2014-10-22 KR KR1020167013624A patent/KR102313314B1/ko active IP Right Grant
- 2014-10-22 EP EP14855465.2A patent/EP3060566B1/fr active Active
- 2014-10-22 MX MX2016005174A patent/MX367707B/es active IP Right Grant
- 2014-10-22 CN CN201480058727.3A patent/CN106414456B/zh active Active
- 2014-10-22 RU RU2016118282A patent/RU2695358C2/ru active
- 2014-10-22 WO PCT/US2014/061734 patent/WO2015061426A1/fr active Application Filing
- 2014-10-22 US US15/031,711 patent/US10301348B2/en active Active
-
2016
- 2016-04-13 IL IL245103A patent/IL245103B/en active IP Right Grant
- 2016-05-10 ZA ZA2016/03118A patent/ZA201603118B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2014340114B2 (en) | 2018-10-18 |
IL245103A0 (en) | 2016-06-30 |
AU2014340114A1 (en) | 2016-05-26 |
EP3060566A4 (fr) | 2017-06-14 |
US20160264613A1 (en) | 2016-09-15 |
JP6534997B2 (ja) | 2019-06-26 |
JP2016535019A (ja) | 2016-11-10 |
MX367707B (es) | 2019-09-03 |
KR20160086852A (ko) | 2016-07-20 |
KR102313314B1 (ko) | 2021-10-19 |
BR112016008901A2 (pt) | 2020-05-12 |
EP3060566B1 (fr) | 2018-09-05 |
CA2927699C (fr) | 2022-07-05 |
CA2927699A1 (fr) | 2015-04-30 |
US10301348B2 (en) | 2019-05-28 |
NZ719740A (en) | 2021-02-26 |
RU2016118282A3 (fr) | 2018-06-18 |
BR112016008901B1 (pt) | 2022-08-23 |
EP3060566A1 (fr) | 2016-08-31 |
CN106414456A (zh) | 2017-02-15 |
RU2016118282A (ru) | 2017-11-28 |
CN106414456B (zh) | 2018-12-14 |
ZA201603118B (en) | 2019-04-24 |
RU2695358C2 (ru) | 2019-07-23 |
WO2015061426A1 (fr) | 2015-04-30 |
IL245103B (en) | 2019-02-28 |
MX2016005174A (es) | 2016-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1222530A1 (zh) | 用於皮膚處理的微閉合及相關方法 | |
IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
HK1221178A1 (zh) | 卡博替尼劑型及其在癌症治療中的使用 | |
HUE042081T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
EP2836270A4 (fr) | Systèmes et procédés liés au traitement de la douleur dorsale | |
HK1220352A1 (zh) | 和神經變性疾病的治療 | |
EP2943189A4 (fr) | Procédés et compositions pour le traitement de maladies de démyélinisation | |
EP2949651A4 (fr) | Benzothiazoles substitués et leurs appllications thérapeutiques pour le traitement de maladies humaines | |
ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
HK1222585A1 (zh) | 用於提供疼痛減輕和麻醉的二氫埃托啡 | |
EP2962693A4 (fr) | Composition pharmaceutique pour la prévention et/ou le traitement d'un cancer | |
PL3228313T3 (pl) | Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny | |
ZA201603118B (en) | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | |
ZA201603117B (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
GB201311361D0 (en) | Compounds and their therapeutic use | |
EP2964227A4 (fr) | Traitement et prophylaxie de maladies rénales | |
EP2986294A4 (fr) | Composés destinés au traitement de la douleur | |
HK1218882A1 (zh) | 用於治療神經退化疾病和其它疾病的組合治療劑和方法 | |
GB201308736D0 (en) | Compounds and their therapeutic use | |
IL246036B (en) | A therapeutic and/or prophylactic substance containing a derivative of 1-indensulfamide for pain | |
ZA201506396B (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases | |
EP2986295A4 (fr) | Composés destinés au traitement de la douleur | |
HUP1300454A2 (hu) | Daganatos betegségek gyógyítására és megelõzésére alkalmas gyógyászati készítmények, és eljárás azok elõállítására | |
GB201317373D0 (en) | Treatment and prevention of cancer |